Navigating Treatment Decisions in Early-Stage Hormone Receptor-Positive Breast Cancer.
Summary
This article discusses the increasing complexity of therapeutic decision-making for early-stage, hormone receptor-positive, HER2-negative breast cancer. It highlights the significance of advances in tumor biology, particularly genomic assays, in improving risk stratification and identifying patients most likely to benefit from chemotherapy. The review also explores current challenges and controversies, such as the use of genomic assays in premenopausal women with node-positive disease. Furthermore, it examines the emerging role of circulating tumor DNA as a prognostic and predictive biomarker.
Analysis
This review is crucial as it highlights the necessity of a personalized approach in treating early-stage HR+ HER2- breast cancer. It emphasizes how risk stratification tools, such as genomic assays and circulating tumor DNA, can optimize therapeutic decisions, thereby avoiding unnecessary treatments and their associated toxicities. For clinical practice, this translates into better patient selection for chemotherapy and a more nuanced management of complex cases, potentially improving patient outcomes and quality of life.